CSL Behring snaps up a closely-held biotech partner and its IL-6 drug — for transplant rejection
Having closely watched and funded a Canadian biotech partner’s IL-6 drug for two and a half years, CSL Behring is snapping it all up.
The buyout of Vitaeris arrives as IL-6 — a proinflammatory interleukin typically associated with arthritis — has garnered interest as a potential culprit for the acute respiratory distress syndrome that plagues certain Covid-19 patients. CSL, though, says it’s still driven by the antibody’s potential for kidney transplant rejection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.